Leptomeningeal Metastatic L858R <i>EGFR</i>-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

<p dir="ltr">Leptomeningeal carcinomatosis (LMC) is a known sequel of metastatic lung cancer and its treatment is challenging. Nevertheless, treatment options for LMC due to metastatic epidermal growth factor receptor-mutant (EGFR-mutant) lung adenocarcinoma are expanding. We present...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Aladdin Kanbour (14442123) (author)
مؤلفون آخرون:	Faroug Salih (21323705) (author), Wafa Abualainin (14442141) (author), Mohamed Abdelrazek (6903689) (author), Lajos Szabados (16561323) (author), Issam Al-Bozom (4711098) (author), Nabil E Omar (18093844) (author)
منشور في:	2022
الموضوعات:	Biomedical and clinical sciences Neurosciences Oncology and carcinogenesis NSCLC non-small-cell lung cancer LMC leptomeningeal carcinomatosis EGFR epidermal growth factor receptor EGFR-TKIs EGFR tyrosine kinase inhibitors osimertinib pulsed erlotinib
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Leptomeningeal Metastatic L858R <i>EGFR</i>-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib

مواد مشابهة